Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2b study of Ciraparantag in healthy volunteers

Next Previous
Trial Profile

A Phase 2b study of Ciraparantag in healthy volunteers

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 04 Dec 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ciraparantag (Primary)
  • Indications Haemorrhage
  • Focus Adverse reactions

Most Recent Events

  • 19 Nov 2020 According to a Covis Pharma media release, the company expect to initiate this study later this year.
  • 20 Apr 2020 New trial record
  • 16 Apr 2020 According to an AMAG Pharmaceuticals media release, the COVID-19 pandemic is an evolving situation and is having an impact on clinical trials globally. The company continues to assess potential impacts to its current clinical development activities for this planned Phase 2b trial in healthy volunteers. The company believes that the COVID-19 pandemic is adversely impacting its current development timelines, including delaying new site initiation and patient enrollment.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top